logo-loader
viewOncoSil Medical Ltd

OncoSil Medical with Proactive at ASX Small and Mid-Cap Conference

OncoSil Medical Ltd (ASX:OSL) chief executive officer Daniel Kenny speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020. 

The medical device company is seeking to advance radiation for cancer patients. OncoSil Medical’s lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.

Quick facts: OncoSil Medical Ltd

Price: 0.12 AUD

ASX:OSL
Market: ASX
Market Cap: $99.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

FastForward Innovations on FCA's green light to medical cannabis listings...

FastForward Innovations Limited's (LON:FFWD) Ed McDermott talks to Proactive London about the FCA's new approach to medical cannabis and as the 'only AIM listed company that has had direct investment in cannabis' this is very significant for the firm. As Mcderrmott explains the UK’s financial...

1 hour, 6 minutes ago

2 min read